Home
About
Capbilities
R&D
Investors
News
Careers
中文
Home
About
Capbilities
R & D
Investors
News
Careers
Press Release
Press Release
2023
2022
2021
2020
2019
2018
2017
Dec 20, 2022
Mabwell Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries
➞
Dec 19, 2022
Mabwell Was Ranked in the "List of New and Innovative Chinese Pharmaceutical Forces"
➞
Dec 01, 2022
Mabwell Published Pre-clinical Study Results of CD47/PD-L1 Bi-specific Antibody 6MW3211
➞
Nov 23, 2022
Dr. Liu Datao, Co-founder and CEO of Mabwell, was Honored as “Sci-Tech Innovation Board Leaders,2022”
➞
Nov 22, 2022
Mabwell and Junshi Announce the Approval of Five Indications for Adalimumab
➞
Nov 21, 2022
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
➞
Nov 18, 2022
Dr. Liu Datao, CEO of Mabwell, Was Invited to Participate in the Live Interview of "International Biopharma Industry Week Shanghai 2022" by Yicai
➞
Nov 16, 2022
Mabwell Awarded "Zhangjiang Life Science Industry New Prominent · 2022"
➞
Nov 11, 2022
Mabwell Ranked the List of Top 20 Most Influential Antibody Pharmaceutical Companies in China 2022
➞
Oct 21, 2022
Wu Zhiyuan, Director of Development Research Center of People's Government of Pudong New Area, and His Entourage Visited Mabwell for Research and Guidance
➞
1
2
3
下一页